AudioScholar Allergy & Immunology Weekly

AudioScholar
  • 0.0 (0)
  • Medicine
  • Weekly

A weekly podcast briefing of the most significant peer-reviewed allergy & immunology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

  1. 2d ago

    EoE guidelines: ≥6 biopsies, gastric/duodenal now optional

    Editor's Pick: European Guidelines on Eosinophilic Esophagitis: Evidence-Based Statements and Recommendations for Diagnosis and Management in Children and Adults. Part 1: Diagnosis, Epidemiology and Natural History (Allergy, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Allergy & Immunology. This week we're covering 10 notable papers spanning eosinophilic gastrointestinal disease, biologic therapy and steroid safety in the airways, and the practical realities of food allergy and immune defici… This week's papers: 1. European Guidelines on Eosinophilic Esophagitis: Evidence-Based Statements and Recommendations for Diagnosis and Management in Children and Adults. Part 1: Dia…. Allergy 2026. 2. Precision Diagnosis and Differentiation of Eosinophilic Colitis and Inflammatory Bowel Disease Using a Tissue-Based Molecular Gene Expression Panel.. Journal of Allergy and Clinical Immunology 2026. 3. Increased Exacerbation Reduction Over Time with Tezepelumab in Severe Asthma: CROSSROADS-4.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 4. Three-year real-world effectiveness of dupilumab in eosinophilic CRSwNP across upper and lower airways.. Allergology International 2026. 5. Systemic Corticosteroid and Tendino-Myopathy Risk in Pediatric Asthma: A Self-Controlled Case Series.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 6. Diagnostic performance and clinical utility of open oral food challenges using double-blind, placebo-controlled food challenges as the reference standard: A sy…. Allergology International 2026. 7. The Spectrum of FPIES severity: A Cohort Analysis of Fully and Partially Met Diagnostic Criteria.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 8. Do School Food Allergy Policies Harm or Help? Quality of Life, Anxiety, and Bullying in Children with Peanut and Tree Nut Allergy.. Journal of Allergy and Clinical Immunology 2026. 9. Pre-Rituximab Immunoglobulin Testing and Baseline Hypogammaglobulinemia Across Rituximab Indications in Adults: A Multisite Retrospective Study.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 10. Demystifying Genetic Workup of Inborn Errors of Immunity.. Current Allergy and Asthma Reports 2026. Listen at https://audioscholar.cc/episode/6522f4es2w

  2. Oct 26

    Rituximab no better than azathioprine for keeping remission

    Editor's Pick: Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial (JAMA, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Allergy & Immunology. This week we're covering 10 notable papers spanning type 2 biologics across the airway, skin, gut and vasculature, anaphylaxis and drug provocation testing, and two rarer corners of the specialty, aspleni… This week's papers: 1. Comparative efficacy and safety of treatments for eosinophilic esophagitis: Systematic review and network meta-analysis of randomized controlled trials.. Journal of Allergy and Clinical Immunology 2026. 2. Total IgE Levels Better Predict Atopic Dermatitis Flares Than Disease Severity, and Both Are Reduced by Dupilumab Treatment.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 3. Personalised dupilumab therapy in severe asthma: real-world dosing interval prolongation among early responders.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 4. Mepolizumab reduces oral corticosteroid use across distinct severe asthma phenotypes: 2-year REALITI-A study.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 5. Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial.. JAMA 2026. 6. Cofactors in Anaphylaxis: Insights From the European Anaphylaxis Registry.. Clinical and Experimental Allergy 2026. 7. Cumulative 600-mg Aspirin Oral Provocation Testing in Skin-Predominant NSAID Hypersensitivity: A Retrospective Cohort Study.. Annals of Allergy, Asthma & Immunology 2026. 8. The Cost-Effectiveness of Requiring Universal and Indefinite Epinephrine Prescriptions for All Patients Receiving Omalizumab to Prevent Anaphylaxis Fatality.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 9. A Link Between Immunoglobulin M Levels and Overwhelming Post-Splenectomy Infection Risk in a National Asplenia Cohort.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 10. Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies.. World Allergy Organization Journal 2026. Listen at https://audioscholar.cc/episode/pckuqpvgh9

  3. Oct 19

    This Week in Allergy & Immunology — Oct 18, 2026

    Editor's Pick: Comparative efficacy and safety of antihistamines, increased antihistamine dosing, and antihistamine adjuncts for chronic urticaria: a systematic review, dose-response, and network meta-analysis of randomized trials (Journal of Allergy and Clinical Immunology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Allergy & Immunology. This week we're covering 10 notable papers spanning chronic urticaria management, biologic and immunotherapy choices in allergic airway disease, and the shifting landscape of food allergy, anaphylaxis, an… This week's papers: 1. Comparative efficacy and safety of antihistamines, increased antihistamine dosing, and antihistamine adjuncts for chronic urticaria: a systematic review, dose-…. Journal of Allergy and Clinical Immunology 2026. 2. Relapse Rates, Time-to-Flare, and Biomarker Predictors Following Omalizumab Gradual De-escalation versus Abrupt Discontinuation in Controlled Chronic Spontaneo…. International Archives of Allergy and Immunology 2026. 3. Second-line dupilumab after anti-IL5/Rα failure: remission rates and clinical outcomes in severe asthma.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 4. Hereditary α-tryptasemia is associated with response to omalizumab in severe allergic asthma.. Annals of Allergy, Asthma & Immunology 2026. 5. Efficacy and Safety of Sublingual versus Subcutaneous Immunotherapy for Patients with Allergic Rhinitis with Asthma: A Systematic Review and Meta-analysis.. International Archives of Allergy and Immunology 2026. 6. A Systematic Review and Meta-Analysis of Temporal Trends in United States' Pediatric Food Allergy.. Annals of Allergy, Asthma & Immunology 2026. 7. International survey of parental and patient perspectives on emerging adrenaline devices for community-based management of anaphylaxis: An EAACI task force rep…. Pediatric Allergy and Immunology 2026. 8. Pediatric Alpha-Gal Syndrome: From Missed Diagnosis to the Burden of Avoidance.. Annals of Allergy, Asthma & Immunology 2026. 9. Systemic Allergic Reactions to mRNA COVID-19 Vaccines: A Randomized Placebo-controlled Trial.. Journal of Allergy and Clinical Immunology 2026. 10. Delayed Drug Hypersensitivity: Mechanistic Advances and Emerging Therapies.. Current Allergy and Asthma Reports 2026. Listen at https://audioscholar.cc/episode/vtv4uck9fz

  4. Oct 12

    Dupilumab improves rhinosinusitis without polyps, not CT

    Editor's Pick: Efficacy of Dupilumab for Patients with Chronic Rhinosinusitis without Nasal Polyps: a Randomized Double-Blind Placebo Controlled Phase II Study (Journal of Allergy and Clinical Immunology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Allergy & Immunology. This week we're covering 10 notable papers spanning type 2 airway disease and endotype-guided therapy, mast cells and the anaphylaxis pathway from genetics to rescue medication, and food allergy preventio… This week's papers: 1. Efficacy of Dupilumab for Patients with Chronic Rhinosinusitis without Nasal Polyps: a Randomized Double-Blind Placebo Controlled Phase II Study.. Journal of Allergy and Clinical Immunology 2026. 2. Integrated-omics endotyping of patients with chronic rhinosinusitis with nasal polyps and their response to glucocorticoid therapy.. Journal of Allergy and Clinical Immunology 2026. 3. Comparative Efficacy of Biologics for Patients with Severe Eosinophilic Asthma: A Network Meta-analysis.. International Archives of Allergy and Immunology 2026. 4. Tryptase Locus Variation Contributes to Normal-Range Basal Serum Tryptase Variability and Is Associated With Anaphylaxis.. Clinical and Experimental Allergy 2026. 5. Mast cell activation syndrome: Global perspectives from a World Allergy Organization survey on knowledge, diagnosis, and access to care.. World Allergy Organization Journal 2026. 6. Pharmacokinetics, pharmacodynamics, and safety of AQST-109 epinephrine 12mg sublingual film: A Phase I pediatric study.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 7. Standards for practical management of drug hypersensitivity reactions to intravenous drugs and proactive early allergy involvement before referral: A WAO State…. World Allergy Organization Journal 2026. 8. Short-term early exposure to cow's milk formula increases the risk of cow's milk allergy: A critical window in early life.. Pediatric Allergy and Immunology 2026. 9. Oral 5-HT3 receptor antagonist for at-home management of acute FPIES episodes in adults: A real-world observational study.. World Allergy Organization Journal 2026. 10. World Allergy Organization Sublingual Immunotherapy Position Paper: 2026 update: Global expert consensus on efficacy, safety, disease modification, and impleme…. World Allergy Organization Journal 2026. Listen at https://audioscholar.cc/episode/4e6wfm3rx8

  5. Oct 5

    Mepolizumab use tied to less airway remodelling at 3 years

    Editor's Pick: Mepolizumab long-term remodeling effect in severe asthma responders: the MESILICO study (Journal of Allergy and Clinical Immunology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Allergy & Immunology. This week we're covering 10 notable papers spanning biologics and the pursuit of remission in eosinophilic disease, the evolving science of food allergy immunotherapy and natural history, and the residual… This week's papers: 1. Mepolizumab long-term remodeling effect in severe asthma responders: the MESILICO study.. Journal of Allergy and Clinical Immunology 2026. 2. Small airway dysfunction as a functional barrier to spirometry-defined clinical remission in severe asthma treated with biologic therapies.. World Allergy Organization Journal 2026. 3. Restoring epithelial health in epithelial-driven disease through an early treat-to-target approach: improving patient care towards clinical remission.. Journal of Allergy and Clinical Immunology 2026. 4. Sustained low disease activity during long-term mepolizumab treatment in FIP1L1::PDGFRA-negative hypereosinophilic syndrome: a multicenter real-world study.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 5. Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy.. Allergy 2026. 6. Inhibition studies to direct oral immunotherapy in walnut-hazelnut co-allergic patients (nut CRACKER study).. Pediatric Allergy and Immunology 2026. 7. Peanut allergy prognosis up to age 12: Oral food challenge-based study in Japanese children.. Pediatric Allergy and Immunology 2026. 8. Palmar hyperlinearity is associated with persistent atopic dermatitis trajectory with high allergic risk: The yamanashi adjunct study of the Japan environment…. Allergology International 2026. 9. Long-term prophylactic treatment and related real-world outcomes of patients with hereditary angioedema in Germany: A retrospective analysis of German claims a…. World Allergy Organization Journal 2026. 10. Under the Drapes: Unmasking the Mechanisms and Clinical Diagnosis of Perioperative Hypersensitivity.. Current Allergy and Asthma Reports 2026. Listen at https://audioscholar.cc/episode/q2c7u6aqbp

  6. Sep 28

    Dupilumab: lower food IgE doesn't mean food tolerance

    Editor's Pick: The Impact of Dupilumab Treatment on the Management of Co-Morbid Food Allergy (The Journal of Allergy and Clinical Immunology: In Practice, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Allergy and Immunology. This week we're covering 10 notable papers spanning the real-world safety of type 2 biologics, the push to define remission across the united airway, and rare disease — from lentiviral gene therapy in W… This week's papers: 1. The Impact of Dupilumab Treatment on the Management of Co-Morbid Food Allergy.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 2. Risk of Respiratory Tract Infections with Asthma Biologics.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 3. Ocular Safety of Dupilumab Compared With IL-5 Inhibitors in Asthma.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 4. Clinical remission in asthma: from symptom control to disease modification.. Annals of Allergy, Asthma & Immunology 2026. 5. Proposed Strategies to Increase the Likelihood of Achieving Remission in CRSwNP by EUFOREA.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 6. Mechanistic and Clinical Updates in Chronic Rhinosinusitis: 2023-2025.. Journal of Allergy and Clinical Immunology 2026. 7. Identifying and Treating Neutrophilic Inflammation in Corticosteroid-Refractory United Airway Disease: A Treatable-Trait Approach.. Annals of Allergy, Asthma & Immunology 2026. 8. Beyond Omalizumab: Emerging Biologic and Small Molecule Therapies in Chronic Spontaneous Urticaria.. Clinical and Experimental Allergy 2026. 9. Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome.. New England Journal of Medicine 2026. 10. Diagnostic Delay in Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors and Implications for Earlier Recognition.. Allergy 2026. Listen at https://audioscholar.cc/episode/e4eht2umk7

  7. Sep 21

    Peanut OFC delabels about a third of sensitised infants

    Editor's Pick: An Oral Food Challenge Is Required for Accurate Diagnosis of Peanut Allergy in Infants Prior to Oral Immunotherapy: Evaluation of the Allergy Development to an Accelerated Pathway to Tolerance Peanut Oral Immunotherapy Program (The Journal of Allergy and Clinical Immunology: In Practice, 2026) Welcome to This Week in Allergy and Immunology. This week we're covering 10 notable papers spanning the early-life origins and prevention of food allergy, the diagnosis and immunotherapy of nut allergy, and a cluster of advances in inborn errors of i… This week's papers: 1. Trial of a Maternal Diet Rich in Eggs and Peanuts to Reduce Infant Allergy.. New England Journal of Medicine 2026. 2. Infant formula introduced within 24 hours of birth increases egg allergy risk.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 3. Anatomical distribution of infant eczema predicts food allergy and food sensitization in early childhood.. The Journal of Allergy and Clinical Immunology: In Practice 2026. 4. An Oral Food Challenge Is Required for Accurate Diagnosis of Peanut Allergy in Infants Prior to Oral Immunotherapy: Evaluation of the Allergy Development to an…. The Journal of Allergy and Clinical Immunology: In Practice 2026. 5. Rate and Predictors of Hazelnut Cross-Desensitization Following Walnut Oral Immunotherapy (Nut CRACKER Study).. The Journal of Allergy and Clinical Immunology: In Practice 2026. 6. ABACHAI - Safety and efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency, a phase II clinical trial.. Journal of Allergy and Clinical Immunology 2026. 7. Exploiting KREC: Time for newborn screening and beyond-proceedings from the First International KREC Consortium Meeting.. Journal of Allergy and Clinical Immunology 2026. 8. Age-stratified CD19+ B cell reference values in children and adolescents -a systematic review and meta-analysis.. Journal of Allergy and Clinical Immunology 2026. 9. Real-World Effectiveness of Tezepelumab for Patients with Severe Asthma in the United States: CROSSROADS-3.. Annals of Allergy, Asthma & Immunology 2026. 10. IgE-Binding Bacterial Components Not Yet Documented in the Allergen Databases and Their Allergenic Mechanisms: An EAACI Position Paper.. Allergy 2026. Listen at https://audioscholar.cc/episode/a26qa9e32x

  8. Sep 14

    This Week in Allergy & Immunology — Sep 13, 2026

    Editor's Pick: Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial (The Lancet, 2026) Welcome to This Week in Allergy and Immunology. This week we're covering 10 notable papers spanning asthma prevention and new airway therapeutics, the social and environmental drivers of asthma morbidity, and practical diagnostics in food and venom a… This week's papers: 1. Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled tria…. The Lancet 2026. 2. Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial.. Nature Medicine 2026. 3. Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase 2b Randomized Clinical Trial.. Allergy 2026. 4. Cumulative Vulnerability to Particulate Matter and Incident Asthma: Joint Effects of Urbanicity, Poverty, and Age in a Nationwide Cohort.. Allergy 2026. 5. Household food hardship and asthma morbidity among United States children with current asthma.. Annals of Allergy, Asthma & Immunology 2026. 6. High Specificity of sIgE to α-/β-Gliadin and Limited Reactivity to Non-Gluten Proteins in Wheat Allergy Dependent on Augmentation Factors (WALDA).. Clinical and Experimental Allergy 2026. 7. Challenge-verified shrimp allergy in a Danish patient cohort throughout 23 years.. International Archives of Allergy and Immunology 2026. 8. As-Needed Versus Regular Medication Use in the Treatment of Allergic Rhinitis in the Pollen Season: A MASK-air Study.. Allergy 2026. 9. Comparative Safety and Treatment Persistence of Aeroallergen and Venom Immunotherapy: A Real-World Patient- and Injection-Level Analysis.. International Archives of Allergy and Immunology 2026. 10. Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases.. Allergy 2026. Listen at https://audioscholar.cc/episode/yzkfk84bdp

See All (26)

About

A weekly podcast briefing of the most significant peer-reviewed allergy & immunology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

Information